Company Profile
| Company | : | GLOBAL HEALTH EDCTP3 JOINT UNDERTAKING |
| City | : | Brussels |
| Country | : | Belgium |
| Industries | : | Government services |
| Website | : | https://www.edctp.org/ |
Company Description
The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association whose members are several EU Member States and Associated countries and several African countries. The GH EDCTP3 JU is established by the Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe (1). It aims at supporting clinical research to deliver solutions to reduce the burden of infectious diseases in sub-Saharan Africa and strengthen research capacities to prepare and respond to emerging infectious diseases.
The first and second European and Developing Countries Clinical Trials Partnership (EDCTP) programmes (2), (3) represent since 2003 a flagship for conducting sound multi-country clinical trials in sub-Saharan Africa, building a true partnership between Europe and Africa, and fostering African leadership in scientific research. These programmes have also contributed to improving linkages between African researchers and African research organisations, which resulted in the launch of four African Regional Networks of Excellence for clinical trials. Moreover, they have strengthened the ethics review capacity and national regulatory authorities in many African countries and contributed to establish relevant organisations in the region.
Building on the positive experience of the previous EDCTP programmes, the GH EDCTP3 JU intends to:
- reduce the socio-economic burden of infectious diseases in sub-Saharan Africa by promoting the development and uptake of new or improved health technologies;
- increase health security in sub-Saharan Africa and globally by strengthening the research and innovation-based capacities for preparedness and response to control infectious diseases.
GH EDCTP3 JU will implement a budget of approximately EUR 1 600 000 000 for the period 2021-2027 and will have a programme office of around 34 highly qualified scientific, clinical and administrative professionals from multi-cultural backgrounds from Europe and Africa, operating in a multilingual context. The budget comes from the European Union Horizon Europe Framework Programme of Research and Innovation, the EDCTP Association member countries and additional contributing partners, such as philanthropic organisations and industry, which will contribute on an ad-hoc basis. More information can be found in the Regulation establishing the JU, notably in its Articles 99-114.
GH EDCTP3 JU is established until 31 December 2031.